DNA Methylation Sequencing Market (2026-2036)

The growth of this market is mainly driven by the rapid adoption of methylation-based liquid biopsy tests for cancer screening and early detection, the growing use of DNA methylation as a biomarker for cancer diagnosis, monitoring, and tissue-of-origin identification, the introduction of bisulfite-free conversion chemistries and multiomic sequencing solutions, and the increasing ability of long-read sequencing platforms to detect methylation natively. In addition, the expansion of epigenetic research in aging, neurology, and rare diseases, the declining cost of sequencing, and the use of machine learning to interpret methylation patterns are further supporting the growth of this market.

The DNA Methylation Sequencing Market, also referred to as the methylation sequencing market, methyl-seq market, or epigenetic sequencing market, comprises the kits and reagents, instruments, software, and services used to map the methylation of cytosine bases across the genome or in targeted regions using sequencing. DNA methylation, most commonly 5-methylcytosine (5mC), is a chemical modification that regulates gene expression without changing the DNA sequence, and abnormal methylation patterns are associated with cancer, aging, neurological disorders, and developmental and rare diseases. The market includes bisulfite conversion kits used in whole-genome bisulfite sequencing (WGBS), reduced representation bisulfite sequencing (RRBS), and targeted bisulfite sequencing; enzymatic and chemical conversion kits, such as enzymatic methyl-seq (EM-seq), the Illumina 5-Base Solution, and biomodal duet solutions that can distinguish 5mC from 5-hydroxymethylcytosine (5hmC); library preparation and target enrichment panels; short-read and long-read sequencers used for methylation analysis; bioinformatics software; and research sequencing services and clinical methylation-based testing services. The market ecosystem extends from reagent and instrument manufacturers to software providers, research service providers, academic and clinical research institutions, pharmaceutical companies, and diagnostic laboratories.

The market is experiencing rapid growth as DNA methylation emerges as one of the most informative biomarkers for cancer detection. Cancer cells shed DNA into the bloodstream, and the methylation patterns of this cell-free DNA (cfDNA) can reveal both the presence of cancer and the tissue in which it originated. Methylation signals are more abundant and more tissue-specific than many genetic mutations, making them well suited to early detection, when tumor DNA in the blood is scarce. This has made methylation sequencing the foundation of several leading cancer screening tests and a central component of the liquid biopsy market.

Clinical cancer screening has become the most important growth driver for the market. GRAIL, whose Galleri multi-cancer early detection test uses a targeted methylation-based sequencing platform, reported Q2 2026 Galleri revenue of USD 42.6 million, up 24%, on more than 61,000 tests, up 35%, has submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA), and anticipates an FDA advisory committee meeting in fall 2026. Results from the NHS-Galleri trial presented at the American Society of Clinical Oncology (ASCO) annual meeting in May 2026 showed that Galleri detected 937 cancers, about 40% at Stage I-II, and was associated with 22% and 26% reductions in Stage IV diagnoses in the second and third screening rounds for 12 prespecified aggressive cancers, while the PATHFINDER 2 study showed a 6.5-fold increase in cancers detected compared with standard recommended screenings. Guardant Health reported Q2 2026 Shield screening revenue of USD 53 million on about 66,000 tests, up from about 16,000 a year earlier, raised its 2026 Shield guidance to USD 218 million to USD 230 million on 270,000 to 285,000 tests, and is launching an FDA-approved, higher-throughput, methylation-only Shield workflow expected to reduce costs by about 15% by the end of 2026. Guardant Health also reports more than 700,000 epigenetic profiles in its data repository, and its Guardant360 Liquid CDx test integrates both genomic and epigenomic content. The growth of these tests is driving demand for high-throughput methylation sequencing, targeted methylation panels, and sequencing capacity in clinical laboratories.

Technology innovation is expanding the capabilities of methylation sequencing. Bisulfite conversion, the long-standing standard, damages DNA and reduces sequence complexity, which limits sensitivity and makes it difficult to analyze low-input samples such as cfDNA. Enzymatic conversion methods such as EM-seq, developed by New England Biolabs and used in the Twist EM-Seq v2 Methylation Detection System, are gentler on DNA and improve library quality. In October 2025, Illumina launched the 5-Base Solution, which uses proprietary conversion chemistry to detect DNA methylation at single-base resolution together with genomic variants from a single sample on NovaSeq and NextSeq 2000 systems, with custom DRAGEN algorithms and Illumina Connected Multiomics for analysis, following an early-access program with more than 50 testers. In February 2026, biomodal and Element Biosciences announced that the biomodal duet +modC (5-base) and duet evoC (6-base) multiomic solutions are compatible with Element AVITI and AVITI24 sequencers, validated at the University of Minnesota Genomics Center for cancer, aging, and neurodegenerative disease research. These solutions enable genetic and epigenetic information to be obtained from the same sample, supporting multiomic research and clinical applications.

Long-read sequencing platforms detect methylation directly from native DNA without conversion. PacBio began the global commercial rollout of its SPRQ-Nx chemistry in 2026, offering whole-genome sequencing at a list price of USD 345 per genome with enhanced methylation detection, while Oxford Nanopore Technologies reported 35% growth in clinical revenue in the first half of 2026. Native methylation detection allows phased, haplotype-resolved methylation analysis across repetitive and complex regions, supporting applications in rare disease, imprinting disorders, and cancer research.

Research applications are also expanding. DNA methylation is used to study gene regulation in cancer, immunology, neuroscience, and development, and methylation-based epigenetic clocks are widely used in aging research to estimate biological age. In addition, methylation sequencing is used in prenatal and reproductive research, rare disease diagnosis, and pharmaceutical biomarker development.

At the same time, the market faces challenges related to the cost of whole-genome methylation sequencing, the complexity of data analysis, and the regulatory and reimbursement requirements for clinical tests. GRAIL reported a net loss of USD 110.2 million in Q2 2026 as it invests in clinical evidence and regulatory approval, illustrating the investment required to bring methylation-based screening to market. As a result, providers that can reduce cost, improve sensitivity with low-input samples, and support clinical-grade workflows are expected to capture the largest share of growth over the forecast period.